In revised results from a phase II clinical trial, Peregrine Pharmaceuticals’ experimental cancer drug bavituximab appeared less effective than in previous reports. While patients with advanced non-small cell lung cancer (NSCLC) receiving a higher dose of bavituximab plus chemotherapy as a second-line treatment survived longer than patients receiving chemotherapy alone or with a lower bavituximab dose, the difference was not statistically significant. In September 2012, preliminary results from the same trial had reported that the higher bavituximab dose doubled patients’ survival time. Since then, an internal review revealed problems with drug vial labeling, which distorted initial results.
Recent discovery of ROS1 gene fusion in a subset of lung cancers has raised clinical interest, because ROS1 fusion-positive cancers are reportedly sensitive to kinase inhibitors. To better understand these tumors, we examined surgically resected non-small cell lung cancers.
IKBKE, a newly identified gene that is activated by tobacco, could be a fresh target for lung cancer therapies. A new study in the journal Oncogene sheds light on the molecular pathways surrounding the activation of IKBKE, which contributes to lung carcinogenesis.
Patients tend to develop resistance to traditional cancer treatments like chemotherapy and radiotherapy. However, the search for genetic therapy targets could yield individualized, powerful treatments that do not decrease in efficacy. Researchers at Florida’s Moffitt Cancer Center found that, in addition to playing a role in the development of chemoresistance, IKBKE is also part of a carcinogenic molecular pathway that can be set off by tobacco smoke. Continue reading…
Radiation therapy is traditionally thought to suppress the immune system. However, it may also stimulate immune cells that can fight against tumor growth. A recent study found that increased levels of the immune cell proteins CD4 and CD8 correlated with improved survival in non-small cell lung cancer (NSCLC) patients who had received radiation therapy after tumor removal. The results suggest that immune cell protein levels could be used to help determine prognosis for patients receiving such “adjuvant therapy.”